ATEC
Alphatec Holdings·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 0
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ATEC
Alphatec Holdings, Inc.
A medical technology company that designs, develops, and markets spinal implant products in the US and globally
Healthcare Equipment and Supplies
--
06/02/2006
NASDAQ Stock Exchange
867
12-31
Common stock
1950 Camino Vida Roble, Carlsbad, California 92008
--
Alphatec Holdings, Inc., was incorporated in Delaware in March 2005. The company is a medical technology company that designs, develops, manufactures and sells surgical treatment products for spinal diseases, focusing on the treatment of factors affecting spinal aging. The company has a comprehensive product portfolio and pipeline that addresses the cervical and thoracic intervertebral areas, covering a variety of spinal diseases. The company's main products focus on the global orthopedic spine disease solutions market. The company's "surgical culture" emphasizes collaborating with spinal surgeons to design and co-develop a range of products. The company has advanced production equipment, unique competitive advantages and enables it to quickly provide solutions to meet the acute needs of doctors and patients. The company's products and systems, functional enhancements, products can appeal to surgeons, a combination of products and systems can provide a comprehensive solution for the safe and successful surgical treatment of spinal diseases. All implants sold by the company in the United States are approved by the U.S. Food and Drug Administration. The company's strategic goal is to become the world's leading independent full-line spine company with a focus on solutions for spinal aging. The aging spine has its own unique characteristics, and its solution is for patients with osteoporosis, vertebral compression fractures, scoliosis or deformity, degenerative disc disease, and spinal stenosis. To further differentiate its solutions, the company has fused minimally invasive technologies and biologics into the company's product portfolio to improve patient outcomes.
Earnings Call
Q1/2025
Estimate EPS-0.12
Actual EPS-0.23
Estimate Revenue168.18M
Actual Revenue169.18M
Alphatec's Q1 2025 Earnings Call: Contradictions on Tariffs, Cash Flow, and Market Expansion Strategies
May 02,2025 07:32
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.05
Actual EPS0.02
Estimate Revenue178.85M
Actual Revenue185.54M
Alphatec's Q2 2025: Contradictions in Robot Launch, EOS Adoption, and Sales Growth Unveiled
Aug 01,2025 11:00
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.02
Actual EPS0.03
Estimate Revenue182.63M
Actual Revenue196.50M
Alphatec's Q3 2025 Earnings Call: Mixed Signals on Sales Growth, EOS Expansion, and Cash Flow Projections
Oct 30,2025 10:05
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ATEC has released its 2025 Q3 earnings. EPS was reported at 0.03, versus the expected -0.02, beating expectations. The chart below visualizes how ATEC has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ATEC has released its 2025 Q3 earnings report, with revenue of 196.50M, reflecting a YoY change of 30.38%, and net profit of -28.58M, showing a YoY change of 27.86%. The Sankey diagram below clearly presents ATEC's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
